The current status and prospect of immunotherapy in colorectal cancer

• Yefei Shu ^[1] ; Song Zheng ^[1]
  1. [1] Zhejiang University

     Zhejiang University

     China

     
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 1, 2024, págs. 39-51
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Metastatic colorectal cancer (mCRC) is a heterogeneous disease. We reviewed the current clinical trials on immunotherapy in metastatic colorectal cancer with high microsatellite instability and microsatellite stability. Owing to the advances in immunotherapy, its use has gradually expanded from second- and third-line therapies to first-line, early neoadjuvant, and adjuvant therapies. Based on current research results, immunotherapy has shown very good results in dMMR/MSI-H patients, whether it is neoadjuvant therapy for operable patients or first-line or multi-line therapy for advanced patients. KEYNOTE 016 study also showed that patients with MSS were basically ineffective in single immunotherapy. Moreover, immunotherapy for colorectal cancer may also require identification of new biomarkers.